Exin Therapeutics offers next-gen neurotherapeutics leverage machine learning, genome editing, & bioelectronic medicine.
Exin Therapeutics has raised $500K in total funding. The most recent round was Non-equity Assistance. The last funding was announced in July 2026.
Exin Therapeutics's investors include Alumni Ventures, Y Combinator, Creative Destruction Lab, Ryan Merket.
Exin Therapeutics is headquartered in South San Francisco, United States.
Exin Therapeutics offers next-gen neurotherapeutics leverage machine learning, genome editing, & bioelectronic medicine.
Exin Therapeutics is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exin Therapeutics — Funding & Investors." VCBacked, July 2, 2026, https://www.vcbacked.co/company/exin-therapeutics. Accessed August 4, 2026.
VCBacked. (2026). Exin Therapeutics — Funding & Investors. Retrieved August 4, 2026, from https://www.vcbacked.co/company/exin-therapeutics
{{cite web |title=Exin Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/exin-therapeutics |website=VCBacked |access-date=August 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated